Cellectis (CLLS)

• Market cap: $362M
• 1 day: -0.83%
• 5 days: -0.28%
• 1 month: -3.49%
• 3 months: -5.26%
• 6 months: -22.91%
• Year to date: -25%
• 1 year: 150%
• 5 years: -77.98%
• 10 years: -89.02%
• Sector: Healthcare
• Industry: Biotechnology

About: Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Employees: 229